INVITED SPEAKER ADAM DURBIN

Targeting transcriptional addiction in pediatric high-risk cancers



WHEN May 10, 2022 12:15 - 13:15 WHERE

100.029, MRB2

Hosted by Prof. dr. Frank Speleman

Training: Adam Durbin is an Assistant Member in the Division of Molecular Oncology at St. Jude Children's Research Hospital (USA). He received scientific and medical training at the University of Toronto and Harvard Medical School and Boston University School of Medicine and a fellowship in the Dana-Farber Cancer Institute/Boston Children's Hospital Pediatric Hematology/Oncology program.

Research: His research focusses on exploiting the systems biology of pediatric solid tumors to identify novel therapeutic strategies and revealed the transcription factor core regulatory circuitry of MYCN-amplified neuroblastoma as well as novel approaches to target CRC-dependent tumors, by inhibiting or degrading epigenetic regulators of the CRC as illustrated by the development of a novel proteolysis-targeted chimaera (PROTAC) agent termed "JQAD1" that selectively recruits the coactivator EP300 for degradation.

Selected papers

Durbin AD*, Zimmerman MW*, Dharia NV*, Abraham BJ, Balboni-Iniguez A, Weichert-Leahey N, He S, Krill-Burger JM, Root DE, Vazquez F, Tsherniak A, Hahn WC, Golub TR, Young RA, Look AT, Stegmaier K. Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry. Nature Genetics 2018. PMID: 30127528

Durbin AD*, Wang T, Wimalasena VK, Zimmerman MW, Li D, Dharia NV, Mariani L, Shendy NAM, Nance S, Patel AG, Shao Y, Mundada M, Maxham L, Park PMC, Sigua LH, Morita K, Saur Conway A, Robichaud AL, Perez-Atayde AR, Bikowitz MJ, Quinn TR, Wiest OG, Easton J, Schonbrunn E, Bulyk ML, Abraham BJ, Stegmaier K*, Look AT*, Qi J*. EP300 selectively controls the enhancer landscape of MYCN-amplified neuroblastoma. Cancer Discovery 2022. . PMID: 34772733

Durbin AD, Pasic I, Wong DK, Hannigan GE, Malkin D. The oncogenic and growth-suppressive functions of the integrin-linked kinase are distinguished by JNK1 expression in human cancer cells. Cell Cycle. 2010. PMID: 20495362

* indicates co- corresponding authorship

This event is co-funded by PrIOMiC, CRIG's International Thematic Network









